FDA Inspection 1179266 — HCG Manavata Cancer Centre
The FDA completed an inspection of HCG Manavata Cancer Centre on Aug 6, 2022 in Nashik. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Aug 6, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Nashik (India)
Additional details
Clinical BA/BE